MTOR and prostate carcinoma: To examine cell cycle progression affected by the AR or PI3K/mTOR inhibitor in prostate cancer cells, LNCaP and 22Rv1 cells were treated with 10 μM of Enzalutamide or 0.2 μM of PF-04691502 or 10 μM of Enzalutamide combined with 0.2 μM of PF-04691502 for 48 hours and DNA content was evaluated using flow cytometry (Fig. 6).